Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.

American Society of Clinical Oncology (ASCO) - Tập 33 Số 15_suppl - Trang 8503-8503 - 2015
Ranjana H. Advani1, Ian W. Flinn2, Jeff P. Sharman3, Catherine Diefenbach4, Kathryn S. Kolibaba5, Oliver W. Press6, Laurie H. Sehn7, Andy I. Chen8, Gilles Salles9, Hervé Tilly10, Bruce D. Cheson11, Sarit Assouline12, Martin Dreyling13, Anton Hagenbeek14, Pier Luigi Zinzani15, Cheryl Jones16, Yu‐Waye Chu16, Jamie Hirata16, Michael Wenger16, Franck Morschhauser17
1Division of Oncology, Stanford University School of Medicine, Stanford, CA
2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
3Willamette Valley Cancer Institute and Research Center, Springfield, OR
4New York University Perlmutter Cancer Center/New York University School of Medicine, New York, NY
5US Oncology and Compass Oncology, Vancouver, WA
6Fred Hutchinson Cancer Research Center, Seattle, WA
7BC Cancer Agency, Vancouver, BC, Canada
8Oregon Health and Science University, Portland, OR
9Hospices Civils de Lyon, Université Claude Bernard, Pierre Bénite, France
10Centre Henri Becquerel, Rouen, France
11Georgetown University Hospital, Washington DC
12Jewish General Hospital, Montreal, QC, Canada
13University of Munich, Munich, Germany
14Academic Medical Center, Amsterdam, Netherlands
15University of Bologna, Bologna, Italy
16Genentech Inc., South San Francisco, CA
17Hôpital Claude Huriez, Lille, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 33 Số 15_suppl

8503-8503

Thông tin tác giả